Real-World Data Show Trastuzumab Deruxtecan Extends Survival in HER2-Low Metastatic Breast Cancer
A real-world cohort of 126 Chinese patients shows trastuzumab deruxtecan delivers a median 9.1 months of progression-free survival in HER2-low ...
Tag: RECIST
CA-125 and RECIST: Key Insights in Ovarian Cancer
Recent advancements in the treatment of ovarian cancer have increasingly focused on understanding the recurrent patterns of the disease and ...
POPULAR NEWS
-
Alloys That Shrink Their Own Grains: New PIX Mechanism Refines Metals With Heat Alone
-
Endurance Exercise Reshapes the Liver in Males and Females Through Distinct Molecular Routes
-
Single Transcription Factor PU.1 Rapidly Converts Fibroblasts into Macrophage-Lineage Cells
-
New Scale Measures How Ready Nurse Educators Really Are for the AI Era